Advertisement

Supportive Care in Cancer

, Volume 26, Issue 3, pp 711–720 | Cite as

The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines

  • Cristhiam M. Rojas-HernandezEmail author
Review Article

Abstract

Cancer-related venous thromboembolism (Wickham et al., Intern Med J 42(6):698–708, 2012) is an important source of morbidity and mortality in that population. The standard of care for the treatment of cancer-related venous thromboembolism (VTE) is a low molecular weight heparin (LMWH) for long periods of time. The favorable clinical trial results for efficacy and safety and availability of direct oral anticoagulants (DOAC) have remodeled the care and options for treatment of venous thromboembolism in the adult population. The data of cancer population-subgroup analysis of those studies have shown that DOAC are as effective and safe as conventional long-term oral anticoagulation with vitamin K antagonists (VKA). Additionally, non-controlled retrospective and prospective cohort data have been published describing efficacy and safety outcomes for the use of DOAC in cancer-related VTE. Altogether, the results from clinical studies have shown that direct oral anticoagulants may represent a treatment option for cancer-related VTE and an alternative to anticoagulation with VKA. Little is known about the patient-centered and system-based variables that determine the use of DOAC outside consensus guidelines, neither is known the impact of different anticoagulant modalities in adherence and quality of life in cancer patients. The objectives of this manuscript are to summarize the clinical trial-based and cohort data of cancer patients treated with DOAC for VTE and to highlight the aspects that may influence adherent to therapy, effectiveness, and safety outcomes in the treatment of cancer-related VTE.

Keywords

Direct oral anticoagulants Low molecular weight heparin Venous thromboembolism 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Rojas-Hernandez declares funding from Daichii-Sankyo related to a clinical trial with edoxaban. No other conflicts to declare.

References

  1. 1.
    Wickham N, Gallus AS, Walters BN, Wilson A, Committee NVPGA (2012) Prevention of venous thromboembolism in patients admitted to Australian hospitals: summary of National Health and Medical Research Council clinical practice guideline. Intern Med J 42(6):698–708.  https://doi.org/10.1111/j.1445-5994.2012.02808.x CrossRefPubMedGoogle Scholar
  2. 2.
    Wun T, White RH (2009) Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Investig 27(Suppl 1):63–74.  https://doi.org/10.1080/07357900802656681 CrossRefGoogle Scholar
  3. 3.
    YB Y, Gau JP, Liu CY, Yang MH, Chiang SC, Hsu HC, Hong YC, Hsiao LT, Liu JH, Chiou TJ, Chen PM, Lee TS, Chou LF, Tzeng CH, Chen TJ (2012) A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. Thromb Haemost 108(2):225–235.  https://doi.org/10.1160/TH12-01-0010 CrossRefGoogle Scholar
  4. 4.
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thrombosis Haemostasis: JTH 5(3):632–634.  https://doi.org/10.1111/j.1538-7836.2007.02374.x CrossRefGoogle Scholar
  5. 5.
    Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A, American Society of Clinical Oncology Clinical P (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(17):2189–2204.  https://doi.org/10.1200/JCO.2013.49.1118 CrossRefPubMedGoogle Scholar
  6. 6.
    Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484–3488.  https://doi.org/10.1182/blood-2002-01-0108 CrossRefPubMedGoogle Scholar
  7. 7.
    Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Buller HR (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thrombosis Haemostasis: JTH 11(1):56–70.  https://doi.org/10.1111/jth.12070 CrossRefGoogle Scholar
  8. 8.
    Mandala M, Falanga A, Roila F, Group EGW (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 22(Suppl 6):vi85–vi92.  https://doi.org/10.1093/annonc/mdr392 PubMedGoogle Scholar
  9. 9.
    Gomez-Outes A, Terleira-Fernandez AI, Lecumberri R, Suarez-Gea ML, Vargas-Castrillon E (2014) Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res 134(4):774–782.  https://doi.org/10.1016/j.thromres.2014.06.020 CrossRefPubMedGoogle Scholar
  10. 10.
    Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY (2014) Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 134(6):1214–1219.  https://doi.org/10.1016/j.thromres.2014.09.039 CrossRefPubMedGoogle Scholar
  11. 11.
    Sardar P, Chatterjee S, Herzog E, Pekler G, Mushiyev S, Pastori LJ, Visco F, Aronow WS (2015) New oral anticoagulants in patients with cancer: current state of evidence. Am J Ther 22(6):460–468.  https://doi.org/10.1097/MJT.0000000000000055 CrossRefPubMedGoogle Scholar
  12. 12.
    Vedovati MC, Germini F, Agnelli G, Becattini C (2015) Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 147(2):475–483.  https://doi.org/10.1378/chest.14-0402 CrossRefPubMedGoogle Scholar
  13. 13.
    Brunetti ND, Gesuete E, De Gennaro L, Correale M, Caldarola P, Gaglione A, Di Biase M (2017) Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: a meta-analysis study. Int J Cardiol 230:214–221.  https://doi.org/10.1016/j.ijcard.2016.12.168 CrossRefPubMedGoogle Scholar
  14. 14.
    Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, Raskob GE, Weitz JI, Yamabe T (2015) Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thrombosis Haemostasis: JTH 13(12):2187–2191.  https://doi.org/10.1111/jth.13153 CrossRefGoogle Scholar
  15. 15.
    Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap AF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1(1):e37–e46.  https://doi.org/10.1016/S2352-3026(14)70018-3 CrossRefPubMedGoogle Scholar
  16. 16.
    Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Buller HR, VTEi H (2016) Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 3(8):e379–e387.  https://doi.org/10.1016/S2352-3026(16)30057-6 CrossRefPubMedGoogle Scholar
  17. 17.
    Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, Hantel S, Feuring M, Kreuzer J (2015) Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 114(1):150–157.  https://doi.org/10.1160/TH14-11-0977 CrossRefPubMedGoogle Scholar
  18. 18.
    Khorana AA, Yannicelli D, McCrae KR, Milentijevic D, Crivera C, Nelson WW, Schein JR (2016) Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res 145:51–53.  https://doi.org/10.1016/j.thromres.2016.07.013 CrossRefPubMedGoogle Scholar
  19. 19.
    Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, Investigators A (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808.  https://doi.org/10.1056/NEJMoa1302507 CrossRefPubMedGoogle Scholar
  20. 20.
    Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thrombosis Haemostasis: JTH 3(4):692–694.  https://doi.org/10.1111/j.1538-7836.2005.01204.x CrossRefGoogle Scholar
  21. 21.
    Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510.  https://doi.org/10.1056/NEJMoa1007903 CrossRefGoogle Scholar
  22. 22.
    Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415.  https://doi.org/10.1056/NEJMoa1306638 CrossRefGoogle Scholar
  23. 23.
    Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, Group R-CS (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352.  https://doi.org/10.1056/NEJMoa0906598 CrossRefPubMedGoogle Scholar
  24. 24.
    Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C, Investigators R-CIT (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764–772.  https://doi.org/10.1161/CIRCULATIONAHA.113.004450 CrossRefPubMedGoogle Scholar
  25. 25.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer I (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153.  https://doi.org/10.1056/NEJMoa025313 CrossRefPubMedGoogle Scholar
  26. 26.
    Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA, Investigators C (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314(7):677–686.  https://doi.org/10.1001/jama.2015.9243 CrossRefPubMedGoogle Scholar
  27. 27.
    van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, Beyer-Westendorf J, Boda Z, Carrier M, Chlumsky J, Decousus H, Garcia D, Gibbs H, Kamphuisen PW, Monreal M, Ockelford P, Pabinger I, Verhamme P, Grosso MA, Buller HR, Raskob GE (2015) Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 114(6):1268–1276.  https://doi.org/10.1160/TH15-06-0452 CrossRefPubMedGoogle Scholar
  28. 28.
    Bott-Kitslaar DM, Saadiq RA, McBane RD, Loprinzi CL, Ashrani AA, Ransone TR, Wolfgram AA, Berentsen MM, Wysokinski WE (2016) Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single-center registry. Am J Med 129(6):615–619.  https://doi.org/10.1016/j.amjmed.2015.12.025 CrossRefPubMedGoogle Scholar
  29. 29.
    Mantha S, Laube E, Miao Y, Sarasohn DM, Parameswaran R, Stefanik S, Brar G, Samedy P, Wills J, Harnicar S, Soff GA (2017) Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 43(2):166–171.  https://doi.org/10.1007/s11239-016-1429-1 CrossRefPubMedGoogle Scholar
  30. 30.
    Pignataro BS, Nishinari K, Cavalcante RN, Centofanti G, Yazbek G, Krutman M, Bomfim GA, Fonseca IY, Teivelis MP, Wolosker N, Sanches SM, Ramacciotti E (2016) Oral rivaroxaban for the treatment of symptomatic venous thromboembolism in 400 patients with active cancer. Clin Appl Thrombosis/Hemostasis.  https://doi.org/10.1177/1076029616677800
  31. 31.
    Ross JA, Miller MM, Rojas Hernandez CM (2017) Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. Thromb Res 150:86–89.  https://doi.org/10.1016/j.thromres.2016.12.016 CrossRefPubMedGoogle Scholar
  32. 32.
    Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A, American Society of Clinical O (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 33(6):654–656.  https://doi.org/10.1200/JCO.2014.59.7351 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Mandala M, Falanga A, Roila F, Group EGW (2010) Venous thromboembolism in cancer patients: ESMO clinical practice guidelines for the management. Ann Oncol 21(Suppl 5):v274–v276.  https://doi.org/10.1093/annonc/mdq199 CrossRefPubMedGoogle Scholar
  34. 34.
    Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A (2016) International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 17(10):e452–e466.  https://doi.org/10.1016/S1470-2045(16)30369-2 CrossRefPubMedGoogle Scholar
  35. 35.
    Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JR, Wells P, Woller SC, Moores L (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352.  https://doi.org/10.1016/j.chest.2015.11.026 CrossRefPubMedGoogle Scholar
  36. 36.
    Di Nisio M, Lee A, Carrier M, Liebman H, Khorana A (2015) Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 13(5):880–883.  https://doi.org/10.1111/jth.12883 CrossRefPubMedGoogle Scholar
  37. 37.
    Jean GW, Kelly K, Mathew J, Larumbe E, Hughes R (2017) Venous thromboembolism treatment outcomes in cancer patients and effect of third-party payers on anticoagulant choice. Supportive Care Cancer 25(1):59–66.  https://doi.org/10.1007/s00520-016-3377-x CrossRefGoogle Scholar
  38. 38.
    Mahe I, Chidiac J, Helfer H, Noble S (2016) Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis. J Thrombosis Haemostasis: JTH 14(11):2107–2113.  https://doi.org/10.1111/jth.13483 CrossRefGoogle Scholar
  39. 39.
    Noble SI, Finlay IG (2005) Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 19(3):197–201.  https://doi.org/10.1191/0269216305pm1008oa CrossRefPubMedGoogle Scholar
  40. 40.
    Seaman S, Nelson A, Noble S (2014) Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence 8:453–461.  https://doi.org/10.2147/PPA.S58595 PubMedPubMedCentralGoogle Scholar
  41. 41.
    Dewilde S, Lloyd AJ, Holm MV, Lee AY (2015) Quality of life of patients experiencing cancer-associated thrombosis. Value Health 18(7):A397–A398.  https://doi.org/10.1016/j.jval.2015.09.906 CrossRefPubMedGoogle Scholar
  42. 42.
    Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G (2015) Assessing patients’ anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica 100(11):1486–1492.  https://doi.org/10.3324/haematol.2015.127126 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A (2013) European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15(5):625–651.  https://doi.org/10.1093/europace/eut083 CrossRefPubMedGoogle Scholar
  44. 44.
    Short NJ, Connors JM (2014) New oral anticoagulants and the cancer patient. Oncologist 19(1):82–93.  https://doi.org/10.1634/theoncologist.2013-0239 CrossRefPubMedGoogle Scholar
  45. 45.
    Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND (2017) Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology 152(5):1014–1022 e1011.  https://doi.org/10.1053/j.gastro.2016.12.018 CrossRefPubMedGoogle Scholar
  46. 46.
    Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373(6):511–520.  https://doi.org/10.1056/NEJMoa1502000 CrossRefPubMedGoogle Scholar
  47. 47.
    Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M, Investigators A (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375(12):1131–1141.  https://doi.org/10.1056/NEJMoa1607887 CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Raval AN, Cigarroa JE, Chung MK, Diaz-Sandoval LJ, Diercks D, Piccini JP, Jung HS, Washam JB, Welch BG, Zazulia AR, Collins SP, American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac C, General Cardiology Committee of the Council on Clinical C, Council on Cardiovascular Disease in the Y, Council on Quality of C, Outcomes R (2017) Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation 135(10):e604–e633.  https://doi.org/10.1161/CIR.0000000000000477 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Section of Benign HematologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations